The FDA has conferred a platform technology designation to Sarepta Therapeutics, aiming to streamline regulatory reviews for gene therapies the company may develop. This status is part of FDA initiatives to expedite innovative treatment approvals, particularly gene therapies targeting rare diseases. Sarepta's designation positions it among the first recipients, underscoring regulatory recognition of its foundational platform and potential to accelerate therapeutic advancement.